A Case Report of Envafolimab in the Treatment of Microsatellite Stable (MSS) Metastatic Colon Cancer

Envafolimab is a novel inhibitor for programmed cell death protein-ligand 1 (PD-L1) that can be administered subcutaneously. It has been found to be effective and safe in the treatment of advanced high microsatellite unstable (MSI-H) / mismatch repair deficient (dMMR) solid tumors. Currently, the ef...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	OncoTargets and therapy 2024-11, Vol.17, p.1137-1144
Hauptverfasser:	Yang, Yunshan, Luo, Xu, Dai, Li, He, Tong, Luo, Siqi, Zhou, Yongjin, Wang, Haibin, Yan, Zhiqiang, Wang, Qian, Jin, Xiangren
Format:	Artikel
Sprache:	eng
Schlagworte:	Colon cancer Dosage and administration Drug therapy Metastasis Monoclonal antibodies Patient outcomes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!